Scientists at King's College London have identified a promising new strategy for fighting Alzheimer's disease that could address several of the condition's damaging effects at the same time. Their research suggests that an experimental drug originally developed for spinal cord injuries may help repair damaged DNA, reduce inflammation, and target biological changes associated with the disease. The drug, known as KCL-286, produced encouraging results in a mouse model of Alzheimer's disease.
Unlike treatments that focus primarily on the buildup of toxic proteins in the brain, this approach targets additional processes that can begin long before the disease reaches its advanced stages. One particularly promising advantage is that KCL-286 has already completed Phase 1 human safety and tolerability trials as part of its earlier development. This could significantly shorten the path toward further clinical testing, although its effectiveness against Alzheimer's in humans has not yet been established.
"KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials. This will dramatically cut down the traditional multi-year timeline required for new drug development," commented Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience at King's College London. The drug is a small molecule that can be taken by mouth, making it potentially more convenient to administer than treatments that require injections or infusions.
Why Alzheimer's Disease Is So Difficult to Treat Alzheimer's disease involves a complicated series of changes in the brain, making it particularly challenging to develop effective treatments. Two of its best-known features are the abnormal accumulation of proteins called amyloid-beta and tau. Amyloid-beta can collect into sticky deposits between nerve cells, while abnormal tau proteins can form tangles inside them.
These changes interfere with normal brain function and are associated with the progressive loss of neurons, the specialized cells responsible for transmitting information throughout the brain. Much of the effort to develop Alzheimer's treatments has focused on these two proteins. Although medications that remove amyloid-beta have demonstrated modest but measurable clinical benefits, they do not fully address the many biological processes involved in the disease.
Researchers are increasingly investigating other changes that may contribute to Alzheimer's, including damage to DNA and inflammation in the brain. Both can appear early in the disease process, making them potentially valuable targets for treatments designed to slow its progression. In the new study, KCL-286 helped repair breaks in DNA and reduce inflammation in mice with Alzheimer's-like disease.
Extract — continue reading at the source.
